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Abstract
The utility of copper-mediated cross-coupling reactions has been significantly increased by the
development of mild reaction conditions and the ability to employ catalytic amounts of copper.
The use of diamine-based ligands has been important in these advances and in this review we
discuss these systems, including the choice of reaction conditions and applications in the synthesis
of pharmaceuticals, natural products and designed materials.
Introduction
Copper-mediated cross-coupling reactions that form C-C, C-N and C-O bonds have a long
history in organic chemistry and have been used in industrial processes.1 A key limitation of
these protocols, however, is the requirement for harsh reaction conditions (high temperatures
and polar solvents) and the need to use stoichiometric or greater quantities of copper.
Following important earlier contributions,2–6 a major improvement came in 2001 when
Buchwald showed that diamine ligands enable the coupling of aryl halides and amides (the
Goldberg reaction) to be performed under much milder conditions using a weak base, non-
polar solvent and temperatures as low as room temperature with a catalytic amount of
copper.7 These new conditions significantly increased the utility of these reactions and there
has since been an avalanche of research into Cu-catalyzed cross-coupling.8–15 These Cu-
catalyzed reactions are robust, can be performed with simple ligands and can be used in the
presence of a plethora of functional groups, making them highly attractive to those engaged
in the synthesis of complex molecular architectures. A range of different useful ligands have
emerged including phenanthrolines,3,16,17α-amino acids,4,12,18,19 1,3-diketones,20,21
imines,22,23 salicylamides24 and others6,25–39 as well as “ligand-free” systems.40–45 A key
advantage of diamine-based ligand systems for copper over some others that have been
brought forward is the large scale access to the ethylenediamine and cyclohexanediamine
backbones (it should be noted there have also been studies with BINAM46–48) and the
commercial availability of the ligands.
The mechanistic details of these reactions have remained somewhat obscure, however,
several recent experimental49–57 and computational studies58 have begun to shed light on
this area. Recently, excellent reviews on Cu-catalyzed cross-coupling have focused on
applications in synthesis,13 developments in methodology11 and the use of amino acid-based
ligands.12 It is the goal of this review to discuss the utilization of diamine ligands in Cu
catalysis and to illustrate the power of these methods with examples drawn from the
synthesis of natural products, pharmaceuticals and novel materials.
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A complementary approach, pioneered by Lam, Chan59,60 and Evans,61 is provided by the
coupling of heteroatom-based nucleophiles with boronic acids in the presence of a copper
salt, typically under an atmosphere of air. These reactions have the advantage of taking
place under mild conditions (often at room temperature under neutral conditions)9,62,63 and
have been utilized in some elegant natural product syntheses.64–66 A number of aryl donors
have been employed in these reactions including aryl stannanes,67 aryl bismuth reagents,68
aryl siloxanes69 and diaryl iodonium salts.70 These reactions can offer unrivalled functional
group tolerance, however, the expense and difficulty of access to the arylating agents can
represent a serious limitation. (Figure 1)
Copper-Catalyzed Methods
In 2001 Buchwald7 showed that the use of diamine ligands allows the Goldberg reaction of
aryl halides to be performed under mild conditions, employing a weak base and non-polar
solvent (Scheme 1).71–75 This discovery has had a significant impact on the synthesis of
natural products and pharmaceuticals (vide infra) and other catalyst systems have since been
described by others.19,22,26,76
These early studies laid out the parameters which have proved useful in later applications of
these catalyst systems. The best solvents are toluene and dioxane, although DMF is better
for very polar amides. A range of different copper sources are active, CuI gives the highest
yields and has the advantage of being cheap and air stable. The choice of base, however, is
much more important. For aryl iodides K3PO4 is best, K2CO3 giving a much slower
reaction. On the other hand, for aryl bromides, which generally react more slowly that aryl
iodides, K3PO4 is often unsuccessful, but K2CO3 is effective. This disparity is thought to
result from the need to match the rate of deprotonation of the amide and the rate of C-N
bond formation. If the rate of deprotonation is relatively too high, then deprotonated amide
accumulates and forms an unreactive cuprate complex.49 Evidence to support this
hypothesis comes from the observation that strong bases such as KHMDS are only
efficacious if added slowly to the reaction mixture. Indeed both K3PO4 and K2CO3 behave
as strong bases in aprotic solvents, but their low solubility ensures slow formation of the
deprotonated amide. Studies were also performed to determine the optimal ligand structure.
A wide range of diamines were examined in these reactions and it was found that ligands
based on either ethylenediamine or cyclohexanediamine provide favorable reactivity.71,77
Ligands derived from the former are generally preferred due to their lower cost. In some
cases the unsubstituted diamines can be used, however, N,N′-dimethyl-substituted ligands
generally provide higher rates and avoid problems associated with undesired N-arylation of
the ligand under the reaction conditions.77 Further substitution at N or the use of larger
groups in place of methyl results in substantially less efficient catalysts (Figure 2).71 Kinetic
studies have indicated that the role of the ligand is to help prevent the formation of less
reactive, multiply ligated cuprate structures. Indeed diamine coordination to the isolated
isolated copper(I) amidate has been shown to generate a species that is both chemically and
kinetically competent for N-arylation.49,52
The reaction is applicable to a range of electron-rich and electron-deficient aryl and
heteroaryl bromides and iodides and even some aryl chlorides. Carbamates are also useful
coupling partners, but the reaction remains most suitable for lactams and primary amides.
Acyclic secondary amides are much more challenging, an efficient reaction can only be
realized for N-aryl or N-methyl amides, except in the case of formamides (Scheme 2).
In a notable application, the Cu-catalyzed arylation of trifluoroacetamide followed by
hydrolysis has been used to allow the use of trifluoroacetamide as an ammonia equivalent in
the synthesis of anilines from aryl halides.78 The same ligand system can be used for the
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synthesis of enamides by the coupling of amides with vinyl halides (Scheme 3).79 This
method has seen considerable application in the synthesis of various natural products (vide
infra). Very similar conditions are also applicable to the coupling of azoles with vinyl
halides.80
Porco had previously detailed the use of copper(I) thiophenecarboxylate (CuTC) as a
catalyst for the amidation of vinyl halides, however this method is limited to terminal vinyl
iodides.81 Porco subsequently recognized that the combination of CuTC and A as
stoichiometric reagents constitutes a useful system.82 Ma has shown that an alternative
catalyst system exploiting N,N-dimethylglycine as ligand is also quite effective.83
Hsung found that diamine ligands allow the successful amidation of alkynyl bromides to
give ynamides (Scheme 4).84 This method permits a complementary access to ynamides,
which are proving to be useful synthons.85
The method was later extended to include sulfonamides by Urabe and Sato.86 Subsequently,
Danheiser87 and Hsung88,89 have discovered alternative conditions which have served to
increase the substrate scope. Recently Evano has documented a new method for the
synthesis of ynamides from 1,1-dibromo-1-alkenes and sulfonamides or carbamates using a
copper-diamine catalyst (Scheme 5).90
The reaction is thought to proceed via initial amidation of the trans C-Br bond of the
dibromoalkene followed by elimination of HBr to yield the ynamide. Evano has also shown
that the formation of either a ketene N,N-acetal or an ynamide from the reaction of a 1,1-
dibromo-1-alkene with amides can be controlled by the choice of solvent – when dioxane is
used the ynamide results, with toluene the N,N-acetal.91 Allenamides are another important
class of synthetic intermediate and can be accessed by the Cu-catalyzed coupling of
nucleophiles with allenyl halides. The first reaction of this class was described by Trost
(Scheme 6).92
Hsung studied a very similar catalyst system and showed that enantiomerically enriched
allenyl halides undergo coupling without isomerization.93 Recently, Bäckvall showed that
the use of a closely related catalyst system employing A as ligand allows the synthesis of
allylic allenamides by the coupling of N-tosyl allylic amines with allenyl halides.94
A number of ligands have been used for the Cu-catalyzed arylation of anilines,18,25,95,96
however, the arylation of heteroarylamines remains challenging as reduction of the aryl
halide electrophile competes with the desired amination.97 Heteroaryl diarylamines have
emerged as an important class of molecules in a range pharmaceuticals, notably protein
kinase inhibitors such as Imatanib.98 One of the best systems for the arylation of
heteroarylamines was disclosed by Liu using diamine ligand A; phenanthroline and proline
proved much less efficient (Scheme 7).99 In order for the reaction of aryl bromides to
proceed efficiently, it is necessary to add potassium iodide to the reaction mixture,
presumably to effect an in situ halide exchange reaction.100
Buchwald has shown that these catalytic systems can also be used for the N-arylation of
indoles77 and for a range of other NH heterocycles (Scheme 8).7,101 For simple substrates
the unsubstituted ligand B is serviceable. However, for more difficult cases (for example,
ortho-substituted aryl halides), N,N′ substituted ligands A and C give better results (in the
case of ligand C, the trans isomer is more effective than the cis). It was demonstrated that
for challenging substrates the N-arylation of the unsubstituted ligand B can occur and the
formation of such N-aryl ligands decreases the rate of the desired arylation as well as
consuming one of the substrates. Aryl iodides and bromides undergo the desired reaction
with the indole nitrogen and selective arylation is possible in the presence of free alcohols,
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anilines, amides and primary amines. A considerable variety of alternative ligand systems
has since become available.16,18,22,23,26,39,44,45,102,103
The use of diamine ligands can also give a favorable outcome for the Cu-catalyzed
vinylation of NH heterocycles.104–108 This approach was applied to the enantioselective
synthesis of β-azaheterocyclic acid derivatives109 by coupling of iodoenoates followed by
enantioselective Cu-catalyzed conjugate reduction (Scheme 9).
Later Xi studied the use of diamine ligands in this reaction in more detail and found that
ethylenediamine is the most efficient, allowing the coupling of a variety of azoles with vinyl
bromides.80 Movassaghi has developed a complementary Pd-catalyzed coupling of pyrroles
and indoles with vinyl triflates.110
Saito disclosed the Cu-catalyzed coupling of aryl iodides and some aryl bromides with tetra-
n-butyl ammonium nitrite to yield aromatic nitro compounds (Scheme 10).111 This was the
first example of a cross-coupling route to these important compounds. The scope of this
approach has recently been significantly extended by the use of a Pd-based catalyst.112
Diamine ligands can also be used in the Cu-catalyzed coupling of sodium azide with aryl
halides, the reaction proving suitable for a range of electron-rich and electron-deficient aryl
bromides.113 Ma has shown that proline is also an effective ligand for copper for this
reaction.114 In a recent study by Molander and Ham, diamine ligands and proline proved
equally efficient in bringing about the coupling of azide with haloaryltrifluoroborates
(Scheme 11).115
The synthesis of aryl azides by Cu-catalyzed coupling is significant because of the utility of
aryl azides in click chemistry116 and the reported difficulty in using Pd-based catalysts to
effect this transformation.117
Diamine ligands are also useful in Cu-catalyzed C-P bond construction (Scheme 12).118 It
was found that with these ligands the efficiency of the coupling of secondary phosphites
with aryl halides is significantly increased, although the coupling of secondary phosphines
can be conducted without the addition of ligand. Subsequently it has been shown that both
proline and picolinic acid can also be employed as ligands in bringing about this
transformation.119
Li has studied the Cu-catalyzed C- or O-arylation of enolates using diamine ligands (Scheme
13).120 In initial screening these authors showed that diamine ligand A provides a far more
active catalyst system than proline or phenanthroline.
Researchers at Merck Frosst have demonstrated that diamine ligands can be useful for the
synthesis of sulfones from sulfinate salts and aryl halides (Scheme 14).121 This represents a
considerable improvement over previous conditions which required the use of stoichiometric
CuI.122 It has subsequently been shown by Ma123 that proline is also an competent ligand in
this transformation and allows the use of some aryl bromides.
The classic Rosenmund-von Braun reaction (the conversion of aryl halides to benzonitriles
with CuCN)124 can be performed in a catalytic manner by using diamine ligand A and
NaCN as the source of cyanide (Scheme 15).125 This method is applicable to aryl iodides
and by addition of 20 mol% KI can be extended to aryl bromides by exploiting an in situ
Finkelstein reaction.100
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These conditions have been used in the synthesis of biologically active molecules126,127 and
a number of variants have since been documented using alternative ligand systems and
cyanide sources.128–131
Applications in the Synthesis of Heterocycles
Transition metal-catalyzed reactions have seen extensive use in the synthesis of
heterocycles.132,133 Interest in these processes stems from their ability to make heterocycles
with unusual substitution patterns that are inaccessible by traditional approaches. The
facility with which Cu/diamine systems can bring about carbon-heteroatom bond formation
has led to the use of these catalysts in a number of novel methods, allowing access to a range
of functionalized heterocycles, typically under mild conditions.
One of the earliest examples of heterocycle synthesis with a copper-diamine catalyst system
was the synthesis of indolines by intramolecular aryl amidation (Scheme 16).71
It was found that the presence of the ligand was essential for reaction to occur.
Intramolecular amidation proceeds much more easily than the intermolecular process, a
phenomenon which has also been observed in analogous Pd-catalyzed reactions.134
Subsequently other systems have been described for such intramolecular amidations.18,135
Evano extended this method to the synthesis of pyrroloindoles (a structural motif found in a
range of biologically active alkaloids) from iodotryptophans (Scheme 17).136
Li has investigated intramolecular amidation reactions of vinyl halides. Initially the
synthesis of β-lactams and alkylideneazetidines was studied (Scheme 18).137 The outcome is
highly dependent on the nature of the substituent on nitrogen, the reaction is successful for
N-tosyl amines but not for unsubstituted or Boc protected amines. The choice of ligand for
copper is also significant, diamine ligand A is very effective, while the use of amino acid
derivatives and phenanthroline gives much lower yields. This method was later extended to
the preparation of larger ring systems.138
It is also possible to synthesize medium-ring nitrogen heterocycles by Cu-catalyzed
arylation of a β-lactam, followed by ring-opening by a pendant amino group (Scheme
19).139 The realization of the reaction is dependent on the competing rates of the desired
arylation of the amide against the undesired intramolecular reaction of the amine to form an
indoline. It was shown that the ratio of these products is strongly influenced by the presence
of the diamine ligand.
Pabba at Albany Molecular Research has shown that N-aryl indazoles may be accessed in a
two-step, one pot protocol from 2-halobenzaldehydes (Scheme 20).140 An aryl hydrazine is
first treated with a 2-halobenzaldehyde under microwave irradiation to furnish an
intermediate aryl hydrazone which is not isolated, CuI and diamine ligand are then added to
the reaction mixture and irradiation continued to afford the indazole. Importantly, it was
shown that in the absence of the diamine ligand only a trace of product is formed.
A two step reaction sequence has also been employed to make indolines via a domino Cu-
catalyzed amidation/nucleophilic substitution process (Scheme 21). The clean inversion
observed at the mesylate center strongly indicates the occurrence of an SN2 substitution
process.141 The reaction can also be used to synthesize 6- and 7-membered rings and a range
of nitrogen protecting groups including Boc, Cbz and acetyl are compatible.
Buchwald used a Cu/diamine catalyst system in the synthesis of N-(2-ketoaryl)amides by
amidation of o-halophenones (Scheme 22).142 The reaction still proceeds in the absence of
ligand, but at a much lower rate. These intermediates can subsequently be engaged in a
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Camps cyclization to generate 2-aryl-4-quinolones or in a McMurry coupling to access
indoles.
Li143,144 and Buchwald145 have both delineated a route to substituted pyrroles based on the
Cu-catalyzed double alkenylation of amides with 1,4-diiodo-1,3-dienes which are available
from the zirconium-146 or titanium-mediated147 coupling of two alkynes (Scheme 23).
Willis has used this method in the synthesis of indoles by the tandem coupling of 2-(2-
haloalkenyl)-aryl halides with carbamates, amides or anilines (Scheme 24).148 This author
had previously published a complementary procedure using Pd-based catalysts.149,150
A Cu-catalyzed amidation of vinyl halides followed by cyclization with iodine provides a
route to oxazoles (Scheme 25).151 This method grants entry to trisubstituted oxazoles, but is
much less efficient for the preparation of mono- and disubstituted oxazoles. The latter could,
however, be accessed via a domino C-N/C-O bond-forming reaction of 1,2-dihaloalkenes. A
related method had been used previously by Glorius in the synthesis of benzoxazoles.152
Scientists at Johnson & Johnson have developed a conceptually similar approach for the
synthesis of benzimidazoles from 1,2-dihaloarenes and amidines (Scheme 26).153
In 2006 Buchwald disclosed a method for the synthesis of pyrroles by a domino Cu-
catalyzed amidation/hydroamidation sequence of haloenynes.154 Pyrazoles could also be
accessed by this method by utilizing bis-Boc hydrazine as nucleophile (Scheme 27).
Preliminary mechanistic studies indicated that the hydroamidation step is both Cu-catalyzed
and base-assisted. Ackermann has applied an allied approach to the synthesis of indoles.155
Lautens has used a diamine ligand in a tandem intramolecular amidation of gem-
dibromoalkenes to generate imidazoindolones (Scheme 28). Such 2-aminoindoles are hard
to generate by more traditional approaches such as the Fischer indole synthesis, but are
structural components of a range of alkaloids.156
In 2007 Buchwald showed that N-alkylbenzimidazoles can be accessed from o-haloanilides
by Cu-catalyzed amidation, followed by acid- or base-mediated cyclization, diamine ligands
proved to be the most effective of those examined (Scheme 29).157
This is an important method as it allows access to regioisomerically pure, substituted, N-
alkyl benzimidazoles. At approximately the same time Ma published a similar process for
the synthesis of benzimidazoles using proline as ligand.158 A complementary Pd-catalyzed
method allows access to N-aryl benzimidazoles by exploiting anilines as the nucleophile.159
Copper-Catalyzed Halide Exchange
In 2002 Buchwald showed that diamine ligands exhibit an accelerating effect on the copper-
catalyzed halide exchange between aryl bromides and inorganic iodides, sometimes referred
to as the aromatic Finkelstein reaction (Scheme 30).100
The reaction provides access to a range of electron-rich and electron-deficient aryl iodides
and has excellent functional group tolerance because of the lack of a strong base in the
reaction medium. The process is efficient for heteroaryl bromides and preliminary studies
also indicated that vinyl bromides are viable substrates. In analogy to the Finkelstein
reaction, this is an equilibrium reaction, the driving force for conversion to the aryl iodide
being provided by the difference in solubility of the sodium halides. The equilibrium
conversion to the aryl iodide is higher in solvents in which NaBr has relatively low
solubility, such as dioxane or pentanol, than in polar solvents in which it is more freely
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soluble such as DMF. These conditions represent a significant improvement over previously
published procedures which required high temperatures (>150 °C), polar solvents and an
excess of copper160,161 or other metal162,163 (although these traditional methods are still
preferred in some contexts164). Later this reaction was incorporated into a domino halide
exchange, cyanation method, allowing the direct conversion of aryl bromides to nitriles125
and in an analogous procedure to produce aryl azides.113 The conditions which make use of
diamine ligands have seen considerable application, particularly in the field of materials
science where it is often advantageous to perform multiple consecutive cross-coupling
reactions on functionalized substrates, thus providing an iterative approach to oligomeric
structures. Aryl bromides are often less reactive than aryl iodides under classical cross-
coupling conditions, this therefore allows an aryl iodide to be “protected” as an aryl bromide
during a synthesis and unmasked as necessary. Vicente showcased this tactic in the synthesis
of thioether phenylene aryl iodide monomers that could participate in further cross-coupling
reactions (Scheme 31).165
Tomioka examined this method in the synthesis of copper complexes of sterically congested
diaryldiazomethanes as part of a study on molecular magnets (Scheme 32).167 The aryl
iodides were later employed in a Suzuki reaction on a stable diazonium intermediate. In an
example which illustrates the functional group tolerance of the reaction, Whitehead made a
complex vinyl iodide intermediate on route to the antibacterial agent (6S)-6-fluoroshikimic
acid (Scheme 33).168
The choice of ligand was crucial to success of the halide exchange, the authors found in a
simplified model system that ligand A was far more effective than B. Once again, the
product was subsequently engaged in Pd-catalyzed cross-coupling reaction.
Spencer also employed this approach in the synthesis of photoactivatable cholesterol
surrogates for studies of HDL formation and cholesterol metabolism (Scheme 34).169
In a particularly impressive example, Rapenne executed this approach in the synthesis of
ruthenium complexes which have potential utility as molecular motors (Scheme 32).166 This
is the first example of the halogen-metal exchange procedure of an organometallic
compound. If the Ru center is coordinated to hydrotris(indazolyl)borate ligand, however, the
reaction is much less successful. The aryl iodide was subsequently used in a Sonogashira
reaction.
Aryl iodides can be key agents in medically important imaging techniques such as positron
emission tomography (PET) and single photon emission computed tomography (SPECT).
With a view to investigating such agents, Sutherland utilized an aromatic Finkelstein
reaction in the synthesis of an iodinated analogue of the noradrenaline re-uptake inhibitor
reboxetine which has potential as an imaging agents for the noradrenaline transporter
(Scheme 35).170 The ability to visualize this receptor within the brain has implications in the
treatment of neurodegenerative and psychiatric disorders.
Sutherland has also used this method in the synthesis of an iodo analogue of the peripheral
benzodiazepine receptor ligand PK11195 which could function as a radiolabelled ligand for
the study of the physiological role of this receptor (Scheme 36).171 It must be noted,
however, that the application of the Cu-catalyzed halide exchange in the synthesis of
radioiodine-labeled compounds may require the reaction to proceed at a higher rate, typical
reaction times for this process are 20–24 h, which could present difficulties when
synthesizing radioactive compounds with nuclei with short half-lives.
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Applications in Pharmaceutical Research
Copper-mediated coupling reactions with diamine ligands have been extensively employed
in the synthesis of novel pharmaceutical agents. Cu-catalyzed arylation is especially
efficient for lactams and these substrates are salient in medicinal chemistry programs. Koert
used such a reaction in the synthesis of new factor Xa inhibitors based on
dianhydrohexitoles for the treatment of thrombosis (Scheme 37).172
At Eli Lilly a Cu-catalyzed aryl amidation was valuable in SAR studies of selective
norepinephrine reuptake inhibitors that have potential in the treatment of depression and
attention-deficit/hyperactivity disorder (Scheme 38).173 A number of derivatives were
prepared with both electron-deficient and electron-neutral aryl halides and the reaction was
amenable to gram scale preparation of intermediates.
Researchers at Abbott have also examined an aryl amidation in the synthesis of dipeptidyl
peptidase IV inhibitors (Scheme 39).174 The somewhat low yield perhaps stems from
undesired deprotonation α to the nitro group leading to side reactions.
Beghyn explored Cu-catalyzed amidation of aryl iodides in the synthesis of arylated
derivatives of the PDE5 inhibitor tadalafil (Scheme 40).175 The low temperature of the
process, long reaction time and high Cu loading are noteworthy. The authors found that
more conventional conditions (for example, performing the reaction at 110 °C) resulted in
complete isomerization from the cis to the thermodynamically more stable trans isomer of
the tetrahydrocarboline (which shows much lower biological activity). Only by running the
reaction at 14 °C was a 95:5 ratio of cis:trans isomers obtained. It was also noted that under
none of the conditions examined was any N-arylation of the indole nitrogen observed.
At the Genomics Institute of the Novartis Research Foundation a Cu-catalyzed amidation
reaction was employed in the synthesis of novel non-nucleoside reverse transcriptase
inhibitors (NNRTIs) for the treatment of HIV (Scheme 41).176 The generality of the
amidation was valuable in the synthesis of a wide range of derivatives with differing
substitution patterns on the N-aryl ring.
At GlaxoSmithKline researchers investigated the amidation of an aryl iodide in the synthesis
of non-brain-penetrant histamine H3 receptor antagonists for the treatment of allergy
conditions (Scheme 42).177
The Cu-catalyzed vinylation of amides is also apposite in medicinal chemistry. Scientists at
BMS exploited diamine ligands in the Cu-catalyzed synthesis of enamides with
aminopeptidase activity from α-amino amides (Scheme 43).178 Both N-Boc protected and
unprotected α-amino amides were suitable substrates in the reaction. N-Cbz protected
substrates, however, gave extensive hydantoin formation. A range of vinyl iodides could be
used, although internal vinyl iodides gave lower conversion.
At Pfizer, a Cu-catalyzed arylation of an oxazolidinone was achieved in one route to the
compound CJ-15,161 which showed promise as a κ-opioid receptor agonist as a non-
addictive analgesic (Scheme 44).179,180 The authors went on to explore the generality of the
method and found the reaction to be effective with a range of electron-deficient and
electron-neutral aryl bromides and iodides and a variety of oxazolidinones, providing a
complementary method to other reported metal-catalyzed arylation reactions of these
substrates with aryl halides.181–184
At Wyeth the amidation of a bromopyridine with a vinylogous amide was used in the
synthesis of squarate inhibitors of mitogen activated protein kinase-activated protein kinase
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2 (MK-2) which are of interest as therapeutic agents for various inflammatory conditions
(Scheme 45).185
At Pfizer the Cu-catalyzed O-arylation of pyridinones with A was expedient in the synthesis
of CRF1 receptor antagonists which have potential for the treatment of stress-related
disorders (Scheme 46).186
This is an interesting result as previous studies of the arylation of 2-pyridinones with Cu/
diamine catalyst systems have indicated that N-arylation dominates.36,187 Such an N-
arylation was utilized at Amgen in the synthesis of inhibitors of receptor tyrosine kinase c-
Kit for the treatment of fibrotic diseases (Scheme 47).188
A number of analogues were synthesized with this method, notably the presence of the
unprotected aminoquinazoline did not interfere with the outcome of the reaction. In a related
example, Steinmetzer performed an intermolecular N-arylation of a pyridazinone in the
synthesis of a matriptase inhibitor which might find application in cancer therapy (Scheme
48).189
Another example of the utilization of a Cu/diamine catalyst system in the arylation of a
pyridazinone has been provided by research at Neurocrine on the synthesis of
thienopyridazinone-based melanin-concentrating Hormone Receptor 1 antagonists (Scheme
49).190 These molecules have potential as anorectic agents for the treatment of obesity.
Multi-gram batches of material were prepared with this protocol.
Cu-catalyzed arylation of sulfonamides191–193 is also a valuable tool in medicinal chemistry.
At Merck, chemists employed a Cu-mediated arylation of benzene sulfonamide with a
complex aryl bromide substrate in the synthesis of dipeptidyl peptidase IV inhibitors for the
treatment of diabetes (Scheme 50).194 A full equivalent of copper was necessary in order to
ensure reproducible yields, although extensive optimization was not attempted.
The coupling of t-butyl carbamate with aryl halides provides a convenient method of
directly synthesizing Boc-protected anilines. At Schering-Plough a combination of CuI and
A was used to catalyze this reaction in the synthesis of melanin-concentrating hormone
receptor-1 antagonists for the treatment of obesity (Scheme 51).195
The arylation of NH heterocycles with Cu/diamine systems77,101 is also pertinent in the
synthesis of pharmaceuticals. At Athersys, Cu-catalyzed arylation of indoles has been
practiced in the synthesis of ramatroban analogues that can act as selective CRTH-2
(chemoattractant receptor-homologous), such compounds have potential in the treatment of
asthma (Scheme 52).196
This method is also illustrated by the work of scientists at IRBM - Merck Research
Laboratories in the synthesis of inhibitors of the hedgehog signaling pathway for the
treatment of various cancers (Scheme 53).197 Note that the difficulty in coupling acyclic
secondary amides allows selective arylation of the NH heterocycle in the presence of the
free amide.
At Merck, an intramolecular Cu-catalyzed arylation of a pyrazole found purpose in the
synthesis of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A for
the treatment of hyperlipidaemia (Scheme 54).198
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Applications in Materials Science
Metal-catalyzed cross-coupling has assumed a central role in the synthesis of novel
materials. Cu-catalyzed processes are especially attractive in this area due to their
robustness, allowing them to be applied to complex, designed molecular architectures
without resorting to specialized equipment (such as dry-box or Schlenk line techniques).
Wang made use of a Cu-catalyzed arylation of an azaindole in the synthesis of molecular
stars with six-fold symmetry (Scheme 55). These molecules exhibit luminescence and form
self-assembled structures in the solid state and as such could be useful in OLEDs.199 The
overall isolated yield of 40% corresponds to an average yield of 86% per C-N coupling
reaction. A Pd-based catalyst, however, was more effective in the amination of this substrate
with a diarylamine. The arylation of carbazoles was also investigated by Yamamoto in the
formation of dendrimers possessing a potential gradient, such materials are important in
organic electronics (Scheme 55).200 Ligands B and C were valuable in synthesizing a range
of dendrimers of varying size. The authors note that the milder reaction conditions provided
by the diamine ligands in the coupling reaction permitted access to large dendrimers which
were inaccessible under the under the harsher, more oxidizing conditions of the classical
Ullmann reaction.201 Burgess used a Cu-catalyzed arylation of carbazole in the synthesis of
energy transfer systems based on squaraines (Scheme 56).202 The goal of this work was to
investigate donor acceptor cassettes connected by a conjugated linker. Pd-catalyzed coupling
reactions were not of merit in effecting this transformation, even though Pd-based methods
had proven efficacious for simpler substrates.
Applications in Natural Product Synthesis
The mild conditions engendered by the application of diamine ligands in Cu-catalyzed
coupling reactions has increasingly encouraged the practitioners of total synthesis to employ
these reactions. It is noticeable that these cross-coupling reactions are often are performed at
the later stages of a synthesis on labile intermediates. The synthesis of macrocyclic
enamides by intramolecular Cu-catalyzed vinylation of amides is an especially valuable tool
in this context.14 Cu-mediated methods provide access to simple enamides from amides and
aryl halides in the presence of a weak base,203 facilitating the use of enamides as protecting
groups for ketones. It should be noted that other catalyst systems have also proven effective
in complex molecule synthesis,13–15 notable syntheses include ziziphine (Ma),204
yatakemycin (Fukuyama)205 and vancomycin (Nicolaou).206
Nishikawa and Isobe took advantage of a Cu/diamine-mediated vinylation of a β-lactam in
the synthesis of model compounds for chartellines (Scheme 57).207 Surprisingly, a mixture
of products resulting from either reaction with the vinyl iodide or vinyl chloride of the
electrophile was obtained, however, under the optimized conditions the desired terminal
product dominated.
Evano investigated a Cu-catalyzed coupling in the synthesis of the sedative cyclopeptide
alkaloid paliurine F (Scheme 58).208
These authors examined a range of reaction conditions, however, the combination of CuI/A
was the most efficacious, the only other system to provide a reasonable quantity of product
was CuTC/NMP. The same author has used very similar procedures in the synthesis of
abyssenine209 and mucronine E.210
Huang at Schering-Plough applied a Cu-mediated copper coupling of an amide and a vinyl
iodide in the synthesis of the potent anticancer natural product psymberin (Scheme 59).211
The same method was later exemplified in the synthesis of a series of analogues.212 This
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example is noteworthy because of the complexity of the amide coupling partner. A similarly
complex nucleophile was utilized by Maier in the synthesis of cruentaren A analogues in
order to perform cytotoxicity studies (Scheme 59).213 This represents an especially
challenging substrate as a result of the risk of the amide undergoing an undesired E1cb
reaction under the basic reaction conditions. Nicolaou and Chen capitalized on the high
functional group tolerance of these methods in the amidation of another sensitive vinyl
iodide in the synthetic campaign which led to the structural revision of the cytotoxic marine
natural product palmerolide A (Scheme 59).214 This approach was later deployed
extensively in the synthesis of analogues.215
A copper-mediated coupling of a vinyl bromide and an oxazolidinone was part of
Movassaghi’s approach to (−)-galbulimima alkaloid 13 (Scheme 60).216 The same author
used a analogous strategy in the synthesis of the related alkaloid himandrine.217 In both
cases the enamide was carried forward as a masked ketone that was revealed later in the
synthesis by treatment with acid.
Charette explored a Cu-catalyzed coupling between t-butyl carbamate and a vinyl iodide in
the synthesis of barrenazine alkaloids (Scheme 61).218 In this case the resulting enamide was
subsequently engaged in a diastereoselective Cu-catalyzed reduction to generate the desired
2-amino ketone.
A Cu-catalyzed coupling of a vinyl iodide with protected prolinamide was employed by
Stanovnik in the synthesis of analogues of the prenylated alkaloid tryprostatin B, a natural
product which has been shown to exhibit cell cycle control (Scheme 62).219
Andersen used an intramolecular Cu-mediated amidation to form a 7-membered ring as a
key step in the synthesis of microtubule-stabilizing ceratamine alkaloids (Scheme 63).220
Cu/diamine catalyst systems have also been exploited for aryl amidation in natural product
syntheses. Panek successfully tested an intramolecular amidation of an aryl bromide as a key
step in the synthesis of geldanamycin, a natural product that shows activity against Hsp90
and is under development for the treatment of cancer (Scheme 59).221 Kobayashi engaged
an intermolecular Cu-catalyzed arylation of an amide in the synthesis of hasubanan
alkaloids, a group closely related to the morphine alkaloids (Scheme 64).222
Evano also applied this method in an intramolecular fashion in this synthesis of the modified
tripeptide natural product chaetominine which shows promising cytotoxicity against a
variety of human cancer cell lines (Scheme 65).223 The authors note that the formation of
this 6-membered ring by amidation proved much more difficult than the 5-membered ring in
an analogous system136 and that the exact combination of ligand, base and solvent was
crucial in ensuring the desired outcome. Attempts to affect the cyclization with catalysts
based on other metals (Pd and Fe) were also unsuccessful.
An intramolecular amidation of an aryl chloride was an important synthetic step in Nakada’s
formal synthesis of physostigmine, an alkaloid of potential medical importance (Scheme
66).224 This example illustrates the greater facility of performing intramolecular reactions,
compared to intermolecular reactions, of aryl chlorides.
Bergman exploited a Cu-catalyzed amidation of an aryl chloride on route to the alkaloid
vasicoline (Scheme 67).225 Trifluoroacetamide was used as a masked ammonia equivalent.
All attempts at a Pd-catalyzed cross-coupling of this substrate in conjunction with a range of
different ammonia equivalents were fruitless. Note that an intermolecular Cu-catalyzed
coupling of an aryl chloride is made feasible here because of the presence of a heteroatom-
directing group.
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Conclusions
There is continuing interest in Cu-catalyzed cross-coupling reactions. Recent advances have
included the demonstration of these reactions at low catalyst loading,226 improved methods
for performing intermolecular reactions at room temperature20,96 and promising studies of
enantioselective reactions.227 Future challenges concern both increasing the scope of
existing reactions and the discovery of catalytic conditions for new coupling reactions.
Another important goal in enabling more efficient syntheses of complex molecular
architectures will be in improving the selectivity of these reactions228,229 in order to reduce
the dependence on protecting groups. The application and development of new diamine
ligands is sure to be important in these advances.
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Fig. 1.
Commercially available diamine ligands
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Fig. 2.
Critical features of diamine-based ligands.
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Scheme 1.
Development of Cu-catalyzed amidation of aryl halides by Buchwald.
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Scheme 2.
Substrate scope of intermolecular Cu-catalyzed amidation.
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Scheme 3.
Synthesis of enamides from vinyl halides.
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Scheme 4.
Synthesis of ynamides according to Hsung.
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Scheme 5.
Synthesis of ynamides according to Evano.
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Scheme 6.
Synthesis of allenamides according to Trost.
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Scheme 7.
Arylation of heteroarylamines according to Liu.
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Scheme 8.
Cu-Catalyzed arylation of NH heterocycles.
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Scheme 9.
Synthesis of β-azaheterocyclic acid derivatives.
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Scheme 10.
Synthesis of aryl nitro compounds according to Saito.
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Scheme 11.
Synthesis of aryl azides by coupling of aryl halides and inorganic azide.
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Scheme 12.
Cu-catalyzed coupling of secondary phosphites and aryl halides.
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Scheme 13.
Selective, intramolecular arylation of enolates studied by Li.
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Scheme 14.
Merck Frosst synthesis of aryl sulfones.
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Scheme 15.
Synthesis of benzonitriles according to Buchwald.
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Scheme 16.
Synthesis of indolines according to Buchwald.
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Scheme 17.
Synthesis of pyrroloindoles according to Evano.
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Scheme 18.
Li’s investigation of intramolecular amidation of vinyl halides.
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Scheme 19.
Synthesis of medium-ring nitrogen heterocycles by tandem cross-coupling/ring expansion.
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Scheme 20.
Albany Molecular Research synthesis of indazoles.
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Scheme 21.
Synthesis of indolines according to Buchwald.
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Scheme 22.
Synthesis of quinolones according to Buchwald.
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Scheme 23.
Synthesis of pyrroles according to Li and Buchwald.
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Scheme 24.
Synthesis of indoles according to Willis.
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Scheme 25.
Synthesis of oxazoles according to Buchwald.
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Scheme 26.
Johnson & Johnson synthesis of benzimidazoles.
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Scheme 27.
Synthesis of pyrrazoles according to Buchwald.
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Scheme 28.
Synthesis of imidazoindolones according to Lautens.
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Scheme 29.
Synthesis of benzimidazoles according to Buchwald.
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Scheme 30.
Cu-catalyzed halide exchange.
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Scheme 31.
Vicente’s approach to thioether phenylene aryl iodide monomers
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Scheme 32.
Applications of the aromatic Finkelstein reaction.
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Scheme 33.
Whitehead’s synthesis of fluoroshikimic acid.
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Scheme 34.
Synthesis of photoactivatable cholesterol surrogates according to Spencer.
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Scheme 35.
Synthesis of an iodinated reboxetine analogue according to Sutherland.
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Scheme 36.
Sutherland’s synthesis of a peripheral benzodiazepine receptor ligand.
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Scheme 37.
Koert’s synthesis of factor Xa inhibitors.
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Scheme 38.
Eli Lilly synthesis of norepinephrine reuptake inhibitors.
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Scheme 39.
Abbott synthesis of dipeptidyl peptidase IV inhibitors.
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Scheme 40.
Beghyn’s study of tadalafil analogues.
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Scheme 41.
Synthesis of non-nucleoside reverse transcriptase inhibitors performed at the Genomics
Institute of the Novartis Research Foundation.
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Scheme 42.
GlaxoSmithKline synthesis of histamine H3 receptor antagonists.
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Scheme 43.
Bristols-Myers Squibb synthesis of enamides with aminopeptidase activity.
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Scheme 44.
Pfizer synthesis of CJ-15,161, a κ-opioid receptor agonist.
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Scheme 45.
Wyeth synthesis of histamine H3 receptor antagonists.
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Scheme 46.
Pfizer synthesis of CRF1 receptor antagonists.
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Scheme 47.
Amgen synthesis of inhibitors of receptor tyrosine kinase c-Kit.
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Scheme 48.
Steinmetzer’s synthesis of a matriptase inhibitor.
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Scheme 49.
Neurocrine synthesis of melanin-concentrating hormone receptor 1 antagonists.
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Scheme 50.
Merck synthesis of dipeptidyl peptidase IV inhibitors.
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Scheme 51.
Schering-Plough synthesis of melanin-concentrating hormone receptor-1 antagonists.
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Scheme 52.
Athersys synthesis of ramatroban analogues.
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Scheme 53.
IRBM - Merck Research Laboratories synthesis of inhibitors of the hedgehog signaling
pathway.
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Scheme 54.
Merck synthesis of agonists of G-protein-coupled niacin receptor 109A.
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Scheme 55.
Applications of Cu/diamine-catalyzed cross-coupling in materials science.
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Scheme 56.
Synthesis of energy transfer systems by Burgess.
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Scheme 57.
Nishikawa and Isobe’s synthesis of chartelline alkaloids.
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Scheme 58.
Evano’s synthesis of paliurine F.
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Scheme 59.
Applications of Cu/diamine-catalyzed cross-coupling in natural products synthesis.
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Scheme 60.
Movassaghi’s synthesis of galbulimima alkaloid 13.
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Scheme 61.
Charette’s synthesis of barrenazine alkaloids.
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Scheme 62.
Stanovnik’s synthesis of tryprostatin B.
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Scheme 63.
Andersen’s synthesis of ceratamine alkaloids.
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Scheme 64.
Kobayashi’s synthesis of hasubanan alkaloids.
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Scheme 65.
Evano’s synthesis of chaetominine.
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Scheme 66.
Nakada’s formal synthesis of physostigmine.
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Scheme 67.
Bergman’s synthesis of vasicoline.
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